Publications (19) Publications in which a researcher has participated

filter_list Biological Psychiatry

2023

  1. Endocannabinoid signaling in brain diseases: Emerging relevance of glial cells

    GLIA, Vol. 71, Núm. 1, pp. 103-126

2021

  1. Garun traumatismoen epe luzeko eragina hipokanpoko CB1 hartzailean

    Osasun zientzak: IV. Ikergazte Nazioarteko Ikerteta Euskaraz. 2021eko ekainaren 9, 10 eta . Gasteiz, Euskal Herria.

  2. Hipokanpoaren mendeko portaeren eta endokannabinoide sistemaren aldaketak loki-lobuluko epilepsiaren animalia-eredu batean

    Osasun zientzak: IV. Ikergazte Nazioarteko Ikerteta Euskaraz. 2021eko ekainaren 9, 10 eta . Gasteiz, Euskal Herria.

  3. Δ9-Tetrahydrocannabinol promotes functional remyelination in the mouse brain

    British Journal of Pharmacology, Vol. 178, Núm. 20, pp. 4176-4192

2020

  1. Cannabinoid control of olfactory processes: The where matters

    Genes, Vol. 11, Núm. 4

  2. P2X7 Receptor-Dependent Layer-Specific Changes in Neuron-Microglia Reactivity in the Prefrontal Cortex of a Phencyclidine Induced Mouse Model of Schizophrenia

    Frontiers in Molecular Neuroscience, Vol. 13

2018

  1. Dual antidepressant duloxetine blocks Nicotinic receptor currents, calcium signals and exocytosis in chromaffin cells stimulated with acetylcholine

    Journal of Pharmacology and Experimental Therapeutics, Vol. 367, Núm. 1, pp. 28-39

  2. Selective up-regulation of cannabinoid CB1 receptor coupling to Go-proteins in suicide victims with mood disorders

    Biochemical Pharmacology, Vol. 157, pp. 258-265

2017

  1. Pregnenolone blocks cannabinoid-induced acute psychotic-like states in mice

    Molecular Psychiatry, Vol. 22, Núm. 11, pp. 1594-1603

  2. Representation-mediated Aversion as a Model to Study Psychotic-like States in Mice

    BIO-PROTOCOL, Vol. 7, Núm. 12

2016

  1. Possible therapeutic doses of cannabinoid type 1 receptor antagonist reverses key alterations in fragile X syndrome mouse model

    Genes, Vol. 7, Núm. 9

2013

  1. Ventral tegmental area cannabinoid type-1 receptors control voluntary exercise performance

    Biological Psychiatry, Vol. 73, Núm. 9, pp. 895-903

2012

  1. Bimodal control of fear-coping strategies by CB 1 cannabinoid receptors

    Journal of Neuroscience, Vol. 32, Núm. 21, pp. 7109-7118

2010

  1. Long-term fluoxetine treatment modulates cannabinoid type 1 receptor-mediated inhibition of adenylyl cyclase in the rat prefrontal cortex through 5-hydroxytryptamine1A receptor-dependent mechanisms

    Molecular Pharmacology, Vol. 77, Núm. 3, pp. 424-434

2008

  1. A potential function of endocannabinoids in the selection of a navigation strategy by rats

    Psychopharmacology, Vol. 198, Núm. 4, pp. 565-576

  2. Role of the cyclic-AMP/PKA cascade and of P/Q-type Ca++ channels in endocannabinoid-mediated long-term depression in the nucleus accumbens

    Neuropharmacology, Vol. 54, Núm. 1, pp. 87-94

2007

  1. CB1 knockout mice display impaired functionality of 5-HT 1A and 5-HT2A/C receptors

    Journal of Neurochemistry, Vol. 103, Núm. 5, pp. 2111-2120

  2. Molecular Components and Functions of the Endocannabinoid System in Mouse Prefrontal Cortex

    PLoS ONE, Vol. 2, Núm. 8

2004

  1. A single In Vivo exposure to cocaine abolishes endocannabinoid-mediated long-term depression in the nucleus accumbens

    Journal of Neuroscience, Vol. 24, Núm. 31, pp. 6939-6945